Treg Therapy in Subclinical Inflammation in Kidney Transplantation
NCT02711826 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 32
Last updated 2025-04-09
Summary
The purpose of this study is:
* To see if polyTregs can reduce inflammation in a transplanted kidney.
* To find out what effects, good or bad, polyTregs will have in the kidney recipient.
* To find out what effects, good or bad, taking everolimus after polyTregs will have in the kidney recipient.
Conditions
- Kidney Transplant
- Adult Living Donor Kidney Transplant Recipients
- Renal Transplant
- Living Kidney Donor
Interventions
- BIOLOGICAL
-
Polyclonal Regulatory T Cells
Participants randomized to polyTregs group will receive a single infusion of 550 ± 450 x 10\^6 polyTregs.
- DRUG
- DRUG
- DRUG
-
Mycophenolate mofetil
All enrolled participants will be on MMF (or MPA below) at the time of study entry at a minimum dose of 1000mg per day.
- DRUG
-
Mycophenolic acid
All enrolled participants will be on MPA (or MMF above) at the time of study entry at a minimum dose of 720mg per day.
- DRUG
-
650 mg acetaminophen, administered 30-60 minutes prior to infusion as pre-medication.
- DRUG
-
Diphenhydramine
25-50 mg diphenhydramine intravenously or by mouth, administered 30-60 minutes prior to infusion as pre-medication.
- PROCEDURE
-
Biopsy, Kidney
- PROCEDURE
-
Blood Draw
- PROCEDURE
-
Leukapheresis
- PROCEDURE
-
IS regimen conversion
Conversion from Tacrolimus, a calcineurin inhibitors (CNI), to Everolimus, an mTOR inhibitor.
Sponsors & Collaborators
-
Clinical Trials in Organ Transplantation
collaborator NETWORK -
National Institute of Allergy and Infectious Diseases (NIAID)
lead NIH
Principal Investigators
-
Flavio Vincenti, MD · University of California at San Francisco
-
Sindhu Chandran, MD · University of California at San Francisco
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2016-09-20
- Primary Completion
- 2023-08-04
- Completion
- 2023-08-04
Countries
- United States
Study Locations
More Related Trials
-
Effect of Different Therapeutic Strategies on Regulatory T Cells in Kidney Transplantation
NCT01640743 ·Status: COMPLETED ·Phase: NA
-
Trial of Adoptive Immunotherapy With TRACT to Prevent Rejection in Living Donor Kidney Transplant Recipients
NCT02145325 ·Status: COMPLETED ·Phase: PHASE1
-
Everolimus Plus Mycophenolic Acid for Kidney Preservation in Liver Transplant Recipients With Impaired Kidney Function
NCT04258423 ·Status: TERMINATED ·Phase: PHASE3
-
Randomized Trial for Mixed Acute Rejection
NCT00771875 ·Status: COMPLETED ·Phase: PHASE2
-
Ex-vivo Expanded Donor Regulatory T Cells for Prevention of Acute Graft-Versus-Host Disease
NCT01795573 ·Status: COMPLETED ·Phase: PHASE1
-
Evaluating Safety and Efficacy of TOL101 Induction Versus Anti-Thymocyte Globulin to Prevent Kidney Transplant Rejection
NCT01154387 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Erythropoietin Therapy to Induce Regulatory T Cells in Liver Transplant Recipients
NCT05325073 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE4
-
A Pilot Study Using Autologous Regulatory T Cell Infusion Zortress (Everolimus) in Renal Transplant Recipients
NCT03284242 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
REgulatory T Cell Therapy to Achieve Immunosuppression REduction
NCT06552169 ·Status: RECRUITING ·Phase: PHASE2
-
TLI, TBI, ATG & Hematopoietic Stem Cell Transplantation and Recipient T Regs Therapy in Living Donor Kidney Transplantation
NCT03943238 ·Status: RECRUITING ·Phase: PHASE1
-
Infusion of T-Regulatory Cells in Kidney Transplant Recipients (The ONE Study)
NCT02091232 ·Status: COMPLETED ·Phase: PHASE1
-
Study in Recipients of Renal Transplant Allograft to Evaluate the Impact of Two Immunosuppressive Regimens
NCT01653847 ·Status: COMPLETED ·Phase: NA
-
Liver Transplantation With Tregs at MGH
NCT03577431 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
Delayed Immunological Tolerance in Patients With Well-functioning Pre-existing HLA-matched Kidney Transplants
NCT05525507 ·Status: RECRUITING ·Phase: PHASE1
-
Combined Blood Stem Cell and Kidney Transplant of One Haplotype Match Living Donor Pairs.
NCT01165762 ·Status: UNKNOWN ·Phase: PHASE1
-
Efficacy and Safety of Human Plasma-derived C1-esterase Inhibitor as add-on to Standard of Care for the Treatment of Refractory Antibody Mediated Rejection (AMR) in Adult Renal Transplant Recipients
NCT03221842 ·Status: TERMINATED ·Phase: PHASE3
-
TACKLE-IT Trial - Treat Acute T Cell Rejection With Evidence and Confidence in Kidney Transplant Recipients
NCT06474273 ·Status: RECRUITING ·Phase: PHASE3
-
Effect of Thymoglobulin Versus Basiliximab on Regulatory T Cell Function in Live Donor Kidney Transplant Recipients
NCT02730715 ·Status: TERMINATED
-
Everolimus Monotherapy as Immunosuppression After Liver Transplant
NCT04063865 ·Status: TERMINATED ·Phase: PHASE3
-
Non-inferiority Study of Safety and Efficacy of Everolimus With Low Dose Tacrolimus to Mycophenolate Mofetil With Standard Dose Tacrolimus in Kidney Transplant Recipients
NCT01025817 ·Status: COMPLETED ·Phase: PHASE3
-
Expanding Liver Transplant Immunosuppression Minimization Via Everolimus
NCT06280950 ·Status: RECRUITING ·Phase: PHASE2
-
Belatacept in Kidney Transplantation of Moderately Sensitized Patients
NCT02130817 ·Status: WITHDRAWN ·Phase: PHASE4
-
mTor-inhibitor (EVERolimus) Based Immunosuppressive Strategies for CNI Minimisation in OLD for Old Renal Transplantation
NCT01028092 ·Status: COMPLETED ·Phase: PHASE3
-
Effect of Everolimus on the Pharmacokinetics of Tacrolimus in Renal Transplant Patients
NCT02077556 ·Status: COMPLETED ·Phase: PHASE4
-
Regimen Optimization Study
NCT02137239 ·Status: COMPLETED ·Phase: PHASE2